



Journal of Enzyme Inhibition and Medicinal Chemistry

ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: http://www.tandfonline.com/loi/ienz20

Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

Jalisa H. Ferguson , Zeus De Los Santos, Saroja N. Devi, Stefan Kaluz, Erwin G. Van Meir, Sarah K. Zingales & Binghe Wang

To cite this article: Jalisa H. Ferguson , Zeus De Los Santos, Saroja N. Devi, Stefan Kaluz, Erwin G. Van Meir, Sarah K. Zingales & Binghe Wang (2017) Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility, Journal of Enzyme Inhibition and Medicinal Chemistry, 32:1, 992-1001, DOI: 10.1080/14756366.2017.1347784

To link to this article: http://dx.doi.org/10.1080/14756366.2017.1347784

© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

0

View supplementary material 🖸



Published online: 02 Aug 2017.



🦉 Submit your article to this journal 🗷



View related articles 🗹



View Crossmark data

Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ienz20

RESEARCH PAPER

Taylor & Francis Taylor & Francis Group

OPEN ACCESS Check for updates

Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

Jalisa H. Ferguson^a (b, Zeus De Los Santos^a, Saroja N. Devi^b, Stefan Kaluz^b, Erwin G. Van Meir^b (b, Sarah K. Zingales^{a,c} (b) and Binghe Wang^a (b)

^aDepartment of Chemistry, Georgia State University, Atlanta, GA, USA; ^bDepartments of Neurosurgery and Hematology and Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, USA; ^cDepartment of Chemistry and Physics, Armstrong State University, Savannah, GA, USA

ABSTRACT

While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound. **ARTICLE HISTORY**

Received 9 May 2017 Revised 23 June 2017 Accepted 24 June 2017

KEYWORDS Hypoxia; solubility; HIF-1

Introduction

Cancer is one of the leading causes of death, second only to heart disease¹. One of the hallmarks of cancer is the formation of hypoxic areas inside of solid tumours². This hypoxic tumour microenvironment leads to many changes such as the upregulation of pro-angiogenic and pro-glycolytic pathways, as well as increases in cell proliferation, genetic instability, and metastatic potential³. A major mediator of the hypoxic response is the hypoxia inducible factor (HIF) pathway⁴. HIF is a heterodimeric transcription factor consisting of two subunits, HIF- α , the stability of which is regulated by oxygen, and HIF-1 β , which is constitutively expressed⁵. There are three known isoforms of HIF- α , HIF-1 α , HIF- 2α , and HIF- 3α , with HIF- 1α being the most commonly expressed and most extensively studied. Under normoxic conditions, HIF- α subunits are hydroxylated by a prolyl hydroxylase (PHD2) using molecular oxygen and then degraded via a VHL-dependent ubiguitination pathway⁶. Under hypoxic conditions, however, HIF- α subunits are stabilised, heterodimerise with HIF-1B and recruit coactivators such as p300 and CBP, to form active transcription complexes that bind to 5'-HREs (hypoxia response elements) in promoter regions of hypoxia-inducible genes⁷. Increased levels of HIF-1 α are linked to cancer progression and poor patient outcome. Therefore, HIF is an attractive target for developing anticancer therapeutics⁸.

A library of 10,000 products containing the 2,2-dimethyl-2*H*chromene moiety⁹ was screened for compounds with HIF inhibitory activity. This led to the identification of a compound designated KCN1 (Figure 1, 1, *N*-((2,2-dimethyl-2*H*-chromen-6-yl)methyl)-3,4-dimethoxy-*N*-phenylbenzenesulfonamide) showing potent inhibition activity (IC₅₀ of ~0.6 μ M) in a HIF-dependent bioassay¹⁰.

Further in vivo studies demonstrated 1's very pronounced inhibitory activity against brain, and pancreatic cancers¹¹. In addition, 1 was well tolerated in mice; daily treatments with 60 mg/kg for up to 12 weeks had minimal side effects¹¹. Neither did 1 nor its analogs demonstrate cytotoxicity, indicating the selective inhibitory effects being based on pathways unique to cancer¹¹. Such results strongly suggest that this is a very promising class of compounds and warrant further studies. In fact, a previously synthesised and analysed class of analogs has been developed, which led to the discovery of 64b (Figure 1, 2, N-cyclobutyl-N-((2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl)methyl)-3,4-dimethoxybenzenesulfonamide) with an IC₅₀ value of \sim 0.3 μ M.¹² However, **1** and its analogs possess poor solubility in water (0.009 µg/mL)¹¹. Therefore, dissolution in DMSO is necessary for in vitro assays and cremophor:ethanolbased formulations are needed for in vivo models. Such a formulation introduces undesirable properties¹². It is well known that the successful development of potential therapeutics relies on more parameters than potency alone. Other properties, including solubility, can play a critical role. Therefore, we are interested in designing water-soluble analogs of 1 and 2 to address this critical aspect of drug development.

CONTACT Sarah K. Zingales Sarah.zingales@armstrong.edu 🗈 Department of Chemistry and Physics, Armstrong State University, Savannah, GA, USA; Binghe Wang Savang@gsu.edu 🗈 Department of Chemistry, Georgia State University, Atlanta, GA, USA

Supplemental data for this article can be accessed <u>here</u>.

© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Figure 1. Lead compounds 1 (KCN1) and 2 (64b)

Materials and methods

Synthesis

General methods and materials

All commercial chemicals were of reagent grade from VWR (Radnor, PA), Aldrich (St. Louis, MO), or Oakwood Chemicals (Estill, SC), and were used without further purification unless otherwise indicated. ¹H and 13C spectra were obtained on a Bruker 400 NMR spectrometer at 400 and 100 MHz, respectively, in deuterated solvent with TMS ($\delta = 0.00$ ppm) or deuterated solvent as internal reference. For all reactions, analytical grade solvent was used. Anhydrous solvents were used for all moisture-sensitive reactions. The Mass Spectrometry Facilities at Georgia State University obtained high-resolution mass spectra on a Waters Micromass Q-TOF (ESI) instrument.

Typical procedure for morpholine substitution (8a-c)

Benzyl bromide (1 equivalent) was dissolved in acetonitrile. Morpholine (1.1 equivalents) and K_2CO_3 (2 equivalents) were added and the reaction was stirred overnight at room temperature. The reaction was filtered through Celite and concentrated to give the product in quantitative yield.

4-(4-Bromobenzyl)morpholine (8a). ¹H NMR (CDCl₃): δ 7.41 (d, J = 8 Hz, 2H), 7.19 (d, J = 8 Hz, 2H), 3.67 (t, J = 4 Hz, 4H), 3.41 (s, 2H), 2.40 (s, 4H) ppm. 13C NMR (CDCl₃): δ 137.0, 131.4, 130.8, 120.9, 66.9, 62.6, 53.6 ppm. HRMS (ESI) *m/z* calculated for C₁₁H₁₅NOBr [(M + H)⁺] 256.0337, found 256.0333.

4-(3-Bromobenzyl)morpholine (8b). ¹H NMR (CDCl₃): δ 7.46 (s, 1H), 7.32 (d, J = 8 Hz, 1H), 7.20 (d, J = 7 Hz, 1H), 7.12 (t, J = 8 Hz, 1H), 3.64 (d, J = 4 Hz, 4H), 3.39 (s, 2H), 2.37 (s, 4H) ppm. 13C NMR (CDCl₃): δ 140.4, 131.9, 130.2, 129.8, 127.6, 122.5, 66.9, 62.7, 53.6 ppm. HRMS (ESI) *m/z* calculated for C₁₁H₁₅NOBr [(M + H)⁺] 256.0337, found 256.0348.

4-(2-Bromobenzyl)morpholine (8c). ¹H NMR (CDCl₃): δ 7.52 (d, J = 8 Hz, 1H), 7.46 (d, J = 7 Hz, 1H), 7.26 (t, J = 7 Hz, 1H), 7.08 (t, J = 7 Hz, 1H), 3.71–3.68 (m, 4H), 3.57 (s, 2H), 2.49–2.48 (m, 4H) ppm. 13C NMR (CDCl₃): δ 137.2, 132.8, 130.8, 128.5, 127.2, 124.7, 67.0, 62.2, 53.6 ppm. HRMS (ESI) m/z calculated for C₁₁H₁₅NOBr [(M + H)⁺] 256.0337, found 256.0348.

Typical procedure for lithium halogen exchange to form aldehydes (9a-c)

Arylbromide (1 equivalent) was dissolved in anhydrous THF under N_2 and cooled in a dry ice and acetone bath for 30 min before treatment with *n*-buLi (1.4 equivalents). After 30 additional minutes, anhydrous DMF (1.4 equivalents) was added and stirring continued 1 h. The reaction was quenched with saturated



 NH_4Cl , taken up in ethyl acetate, washed with brine, dried over Mg_2SO_4 , and concentrated *in vacuo*. Purification by column chromatography was performed in 4:1 hexanes/ethyl acetate.

4-(Morpholinomethyl)benzaldehyde (9a). Yield: 74%. ¹H NMR (CDCl₃): δ 9.96 (s, 1H), 7.81 (d, J = 8 Hz, 2H), 7.49 (d, J = 8 Hz, 2H), 3.68–3.68 (m, 4H), 3.54 (s, 2H), 2.43 (m, 4H) ppm. 13C NMR (CDCl₃): δ 191.9, 145.3, 135.6, 129.8, 129.5, 66.9, 63.0, 53.6 ppm. HRMS *m/z* calculated for C₁₂H₁₆NO₂ [(M + H)⁺] 206.1181, found 206.1182.

3-(Morpholinomethyl)benzaldehyde (9b). Yield: 88%. ¹H NMR (CDCl₃): δ 9.92 (s, 1H), 7.77 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.54 (d, J = 8 Hz, 2H), 7.41 (t, J = 8 Hz, 1H), 3.63 (m, 4H), 3.50 (s, 2H), 2.39 (m, 4H) ppm. 13C NMR (CDCl₃): δ 192.2, 138.8, 136.5, 135.2, 130.2, 129.0, 128.7, 66.7, 62.6, 53.4 ppm. HRMS *m*/*z* calculated for C₁₂H₁₆NO₂ [(M + H)⁺] 206.1181, found 206.1183.

2-(Morpholinomethyl)benzaldehyde (9c). Yield: 85%. ¹H NMR (CDCl₃): δ 10.37 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 7.37–7.33 (m, 2H), 3.76 (s, 2H), 3.58–3.57 (m, 4H), 2.40–2.39 (m, 4H) ppm. 13C NMR (CDCl₃): δ 192.0, 140.4, 135.0, 133.2, 130.6, 129.4, 127.9, 67.0, 66.9, 60.0, 53.5, 53.3 ppm. HRMS *m/z* calculated for C₁₂H₁₆NO₂ [(M + H)⁺] 206.1181, found 206.1186.

Procedure for 2,2-dimethyl-2H-chromene-6-carbaldehyde (12)

Synthesised and purified as described in previous examples¹³. Yield: 37% over two steps. ¹H NMR (CDCl₃): δ 9.83 (s, 1H), 7.64 (d, J = 8 Hz, 1H), 7.52 (s, 1H), 6.87 (d, J = 8 Hz, 2H), 6.37 (d, J = 10 Hz, 1H), 5.70 (d, J = 10 Hz, 1H), 1.47 (s, 6H) ppm.

Typical procedure for reductive amination with aniline (10a–d, 14a)

Aldehyde (1 equivalent), NaBH₄ (1.5 equivalents), and InCl₃ (0.15 equivalents) were dissolved in anhydrous ACN under inert gas. Aniline (1.5 equivalents) was added and the reaction was stirred until completion as monitored by TLC (typically ~20 min). The reaction was quenched with saturated NH₄Cl, taken up in ethyl acetate, washed with brine, dried over MgSO₄, and concentrated. Column chromatography (1:1 hexane/ethyl acetate) was used to yield the final pure product.

N-(4-(Morpholinomethyl)benzyl)aniline (10a). Yield: 60%. ¹H NMR (CDCl₃): δ 7.23–7.17 (m, 4H), 6.79–6.66 (m, 5H), 4.34 (s, 2H), 3.74 (m, 4H), 3.52 (s, 2H), 2.74 (m, 4H) ppm. 13C NMR (CDCl₃): δ 148.2, 138.4, 136.8, 129.5, 129.3, 127.5, 118.6, 117.6, 115.1, 112.9, 67.0, 63.2, 53.6, 48.1 ppm. HRMS *m/z* (ESI) calculated for C₁₈H₂₃N₂O [(M + H)⁺] 283.1810, found 283.1805.

N-(3-(Morpholinomethyl)benzyl)aniline (10b). Yield: 60%. ¹H NMR (CDCl₃): δ 7.36-7.17 (m, 6H), 6.76-6.65 (m, 3H), 4.35 (s, 2H), 3.73–3.72 (m, 4H), 3.52 (s, 2H), 2.45 (m, 4H) ppm. 13C NMR (CDCl₃): 148.1, 139.5, 138.1, 129.3, 128.6, 128.3, 128.1, 126.4, 117.6, 112.9, 67.0, 63.4, 53.6, 48.3 ppm. HRMS (ESI) *m/z* calculated for $C_{18}H_{23}N_2O$ [(M + H)⁺] 283.1810, found 283.1809.

N-(2-(Morpholinomethyl)benzyl)aniline (10c). Yield: 54%. ¹H NMR (CDCl₃): δ 7.44 (d, J = 7 Hz, 1H), 7.32–7.22 (m, 5H), 6.75 (d, J = 7 Hz, 3H), 5.37 (bs, 1H), 4.39 (s, 2H), 3.75 (m, 4H), 3.57 (s, 2H), 2.51 (m, 4H) ppm. 13C NMR (CDCl₃): 148.6, 138.9, 135.8, 131.5, 130.0, 129.3, 128.2, 127.2, 117.4, 113.1, 67.1, 61.7, 53.5, 46.9 ppm. HRMS (ESI) m/z calculated for $C_{18}H_{23}N_2O$ [(M + H)⁺] 283.1810, found 283.1805.

N-(4-Morpholinobenzyl)aniline (10d). Yield: 25%. ¹H NMR (CDCl₃): δ 7.33 (d, J = 8 Hz, 2H), 7.22 (t, J = 8 Hz, 2H), 6.94 (d, J = 8 Hz, 2H), 6.76 (t, J = 7 Hz, 1H), 6.68 (d, J = 8 Hz, 2H), 4.28 (s, 2H), 4.00 (bs, 1H), 3.91–3.90 (m, 4H), 3.19–3.18 (m, 4H) ppm. 13C NMR (CDCl₃): δ 150.6, 148.3, 130.8, 129.3, 128.7, 117.5, 115.9, 112.9, 67.0, 49.5, 47.8 ppm. HRMS (ESI) m/z calculated for $C_{17}H_{21}N_2O$ [(M + H)⁺] 269.1654, found 269.1659.

N-((*2*,2-Dimethyl-2H-chromen-6-yl)methyl)aniline (14a). Yield: 80%. ¹H NMR (CDCl₃): δ 7.26–7.21 (m, 3H), 6.97 (d, J = 7 Hz, 1H), 6.87 (d, J = 8 Hz, 1H), 6.79–6.72 (m, 3H), 6.39 (d, J = 10 Hz, 1H), 5.68 (d, J = 10 Hz, 1H), 4.37 (s, 2H), 4.06 (bs, 1H) 1.52 (s, 6H) ppm. 13C NMR (CDCl₃): δ 150.8, 148.5, 130.6, 129.2, 128.8, 126.5, 125.5, 122.5, 121.1, 120.5, 117.4, 113.2, 76.4, 43.1, 28.1 ppm. HRMS (ESI) *m/z* calculated for C₁₈H₂₀NO [(M + H)⁺] 266.1545, found 266.1548.

Typical procedure for reductive amination with cyclobutyl and alkylmorpholino amines (11a–d, 13a–b, 14b)

Aldehyde (1 equivalent) and amine (1 equivalent) were dissolved in anhydrous MeOH under inert gas and the reaction was stirred overnight at room temperature. $NaBH_4$ (1.6 equiv.) was added and the reaction stirred for an additional hour. The reaction was quenched with NaOH (1 M), stirred for an hour, then taken up in ethyl acetate, washed with brine, dried over MgSO₄, concentrated, and taken directly to the next step without further purification.

N-(4-(Morpholinomethyl)benzyl)cyclobutanamine (11a). Crude yield: 89%. ¹H NMR (CDCl₃): δ 7.32–7.26 (m, 4H), 3.69–3.68 (m, 4H), 3.47 (s, 2H), 3.29 (quintet, J = 7 Hz, 1H), 2.42 (m, 4H), 2.22–2.21 (m, 2H), 1.63–1.62 (m, 4H) ppm. 13C NMR (CDCl₃): δ 139.3, 136.3, 129.4, 128.1, 67.0, 63.2, 53.6, 50.8, 31.2, 31.1, 15.0, 14.8 ppm. HRMS (ESI) *m/z* calculated for C₁₆H₂₅N₂O [(M+H)⁺] 261.1967, found 261.1961.

N-(3-(Morpholinomethyl)benzyl)cyclobutanamine (11b). Crude yield: 88% unpurified. ¹H NMR (CDCl₃): 7.32–7.19 (m, 4H), 3.69 (m, 6H), 3.49–3.48 (m, 2H), 3.30 (quintet, J = 7 Hz, 1H), 2.43 (m, 4H), 2.24–2.20 (m, 2H), 1.74–1.63 (m, 4H) ppm. 13C NMR (CDCl₃): 140.3, 137.9, 129.0, 128.6, 127.8, 127.1, 66.9, 63.1, 53.7, 53.6, 51.0, 31.1, 14.8 ppm. HRMS (ESI) *m/z* calculated for C₁₆H₂₅N₂O [(M + H)⁺] 261.1967, found 261.1963.

N-(2-(Morpholinomethyl)benzyl)cyclobutanamine (11c). Crude yield: 94%. ¹H NMR (CDCl₃): δ 7.30–7.16 (m, 4H), 3.67 (s, 2H), 3.64 (s, 4H), 3.49 (s, 2H), 3.28–3.27 (m, 1H), 2.53 (s, 1H), 2.43 (s, 4H), 2.19–2.17 (m, 2H), 1.70–1.63 (m, 4H) ppm. 13C NMR (CDCl₃): δ 140.3, 135.7, 131.3, 130.6, 127.9, 126.7, 67.0, 61.7, 53.9, 53.4, 49.7, 31.0, 15.1 ppm. HRMS (ESI) m/z calculated for $C_{16}H_{25}N_2O$ [(M + H)⁺] 261.1967, found 261.1962.

N-(4-Morpholinobenzyl)cyclobutanamine (11d). Crude yield: 90%. ¹H NMR (CDCI₃): δ 7.22 (d, J = 8 Hz, 2H), 6.87 (d, J = 8 Hz, 2H), 3.86–3.84 (m, 4H), 3.62 (s, 2H), 3.28 (quintet, J = 6.8 Hz, 1H), 3.14–3.11 (m, 4H), 2.22–2.19 (m, 2H), 1.70–1.62 (m, 4H) ppm. 13C NMR (CDCI₃): δ 150.3, 131.9, 129.1, 115.7, 66.9, 53.5, 50.4, 49.5, 31.1, 14.8 ppm. HRMS (ESI) *m/z* calculated for C₁₅H₂₃N₂O [(M + H)⁺] 247.1810, found 247.1819.

N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-2-morpholinoethan-

amine (13a). Crude yield: 90%. ¹H NMR (CDCI₃): δ 7.16 (dd, J=8, 22 Hz, 1H), 7.00 (d, J=8 Hz, 1H), 6.69 (d, J=8 Hz, 1H), 6.27 (d, J=10 Hz, 1H), 5.57 (d, J=10 Hz, 1H), 3.72-3.64 (m, 6H), 3.09 (s, 1H), 2.66-2.64 (m, 2H), 2.47-2.44 (m, 2H), 2.35 (m, 4H), 1.39 (s, 6H) ppm. 13C NMR (CDCI₃): δ 152.0, 130.9, 128.9, 128.7, 126.2, 122.2, 121.5, 116.1, 76.1, 66.9, 57.9, 53.6, 53.2, 44.9, 27.9 ppm. HRMS (ESI) *m/z* calculated for C₁₈H₂₇N₂O₂ [(M + H)⁺] 303.2073, found 303.2063.

N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-3-morpholinopropan-1-

amine (13b). Crude yield: 89%. ¹H NMR (CDCl₃): δ 7.18–7.10 (m, 1H), 6.98 (d, J = 8 Hz, 1H), 6.67 (d, J = 8 Hz, 1H), 6.24 (d, J = 10 Hz, 1H), 5.55 (d, J = 10 Hz, 1H), 3.68–3.62 (m, 6H), 2.63 (m, 2H), 2.37–2.35 (m, 4H), 1.67–1.58 (m, 2H), 1.58 (m, 2H), 1.37 (s, 6H) ppm. 13C NMR (CDCl₃): δ 151.9, 132.3, 130.9, 128.8, 126.1, 122.3, 121.5, 116.1, 73.9, 66.9, 57.3, 53.7, 47.9, 29.6, 27.9, 26.4 ppm. HRMS (ESI) m/z calculated for $C_{19}H_{29}N_2O_2$ [(M + H)⁺] 317.2229, found 317.2237.

N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)aniline (14a). Crude yield: 90%. ¹H NMR (CDCl₃): δ 7.26–7.21 (m, 3H), 6.96 (d, J = 7 Hz, 1H), 6.87 (d, J = 8 Hz, 1H), 6.79–6.72 (m, 3H), 6.39 (d, J = 10 Hz, 1H), 5.68 (d, J = 10 Hz, 1H), 4.73 (s, 2H), 4.06 (bs, 1H), 1.52 (s, 6H) ppm. 13C NMR (CDCl₃): δ 150.8, 148.5, 130.6, 129.2, 128.8, 126.5, 125.5, 122.5, 121.1, 120.5, 117.4, 113.2, 76.4, 43.1, 28.2 ppm. HRMS (ESI) m/z calculated for C₁₈H₂₀NO [(M + H)⁺] 266.1545, found 266.1548.

N-((*2*,*2*-*Dimethyl*-2H-*chromen*-6-*yl*)*methyl*)*cyclobutanamine* (14*b*). Crude yield: 98%. ¹H NMR (CDCl₃): δ 7.03 (d, *J* = 8 Hz, 1H), 6.95 (s, 1H), 6.72 (d, *J* = 8 Hz, 1H), 6.31 (d, *J* = 10 Hz, 1H), 5.60 (d, *J* = 10 Hz, 1H), 3.56 (s, 2H), 3.32–3.26 (m, 1H), 2.22 (m, 2H), 1.72–1.69 (m, 4H), 1.42 (s, 6H) ppm. 13C NMR (CDCl₃): δ 151.9, 132.5, 130.8, 128.9, 126.2, 122.3, 121.2, 116.1, 76.1, 53.5, 50.5, 31.1, 27.9, 14.8 ppm. HRMS (ESI) *m/z* calculated for C₁₆H₂₂NO [(M + H)⁺] 244.1701, found 244.1697.

Typical procedure for sulfonylation with 3,4-dimethoxybenzenesulfonyl chloride (3a–d, 4a–d, 5a–b)

Amine (1 equivalent) was dissolved in DCM. K_2CO_3 (2 equivalents) and 3,4-dimethoxybenzenesulfonyl chloride (2 equivalents) were added. The reaction was stirred overnight at room temperature, then washed with brine, dried over MgSO₄, and concentrated. The product was purified by column chromatography in 4:1 or 1:1 hexane/ethyl acetate.

3,4-Dimethoxy-N-(4-(morpholinomethyl)benzyl)-N-phenylbenzene-

sulfonamide (3a). Yield: 11%. ¹H NMR (CDCl₃): δ 7.36 (d, J = 7 Hz, 1H), 7.35 (s, 1H), 7.22–7.20 (m, 6H), 7.04–7.02 (m, 2H), 6.97–6.94 (m, 2H), 4.72 (s, 1H), 3.98 (s, 3H), 3.77 (s, 3H), 3.70–3.69 (m, 4H),

3.44 (s, 2H), 2.40 (m, 4H) ppm. 13C NMR (CDCl₃): δ 152.6, 148.7, 139.2, 135.0, 130.2, 129.2, 129.0, 128.8, 128.4, 127.8, 127.5, 121.4, 110.4, 110.4, 66.9, 63.0, 56.2, 56.01, 54.4, 53.5 ppm. HRMS (ESI) *m/z* calculated for C₂₆H₃₁N₂O₅S [(M + H)⁺] 483.1954, found 483.1956.

3,4-Dimethoxy-N-(3-(morpholinomethyl)benzyl)-N-phenylbenzene-

sulfonamide (3b). Yield: 64%. ¹H NMR (CDCl₃): δ 7.36–7.31 (m, 2H), 7.17–7.09 (m, 7H), 6.98–6.91 (m, 4H), 4.69 (s, 2H), 3.95 (s, 3H), 3.73 (s, 3H), 3.63 (t, *J* = 4 Hz, 4H), 3.39–3.37 (m, 2H), 2.27 (m, 4H) ppm. 13C NMR (CDCl₃): δ 152.7, 148.8, 139.1, 137.8, 135.9, 130.1, 129.6, 129.1, 128.8, 128.6, 128.4, 127.8, 127.6, 121.5, 110.5, 67.0, 63.2, 56.3, 56.2, 54.5, 53.5, 48.5 ppm. HRMS (ESI) *m/z* calculated for C₂₆H₃₁N₂O₅S [(M + H)⁺] 483.1948, found 483.1928.

3,4-Dimethoxy-N-(2-(morpholinomethyl)benzyl)-N-phenylbenzene-

sulfonamide (*3c*). Yield: 47%. ¹H NMR (CDCl₃): δ 7.36 (d, J = 8 Hz, 1H), 7.21–7.18 (m, 4H), 7.10–7.09 (m, 3H), 7.03–7.01 (m, 2H), 6.95–6.93 (m, 2H), 4.97 (s, 2H), 3.97 (s, 3H), 3.75 (s, 3H), 3.62 (m, 4H), 3.48 (s, 2H), 2.35 (m, 4H) ppm. 13C NMR (CDCl₃): δ 152.7, 148.8, 139.5, 136.1, 135.2, 130.8, 130.2, 129.7, 128.9, 128.8, 127.8, 127.4, 127.3, 121.7, 110.7, 110.5, 67.2, 61.1, 56.3, 56.2, 53.6, 51.3, 31.0, 30.8, 13.6 ppm. HRMS (ESI) *m/z* calculated for C₂₆H₃₁N₂O₅S [(M + H)⁺] 483.1948, found 483.1941.

3,4-Dimethoxy-N-(4-morpholinobenzyl)-N-phenylbenzenesulfona-

mide (3*d*). Yield: 40%. ¹H NMR (CDCl₃): δ 7.35 (d, J = 8 Hz, 1H), 7.21 (m, 3H), 7.12 (d, J = 7 Hz, 2H), 7.01–6.93 (m, 4H), 6.76 (d, J = 7 Hz, 2H), 4.65 (s, 2H), 3.97 (s, 3H), 3.84–3.83 (m, 4H), 3.77 (s, 3H), 3.11–3.10 (m, 4H) ppm. ¹³C NMR (CDCl₃): δ 152.5, 150.5, 148.7, 139.2, 130.3, 129.6, 129.1, 128.7, 127.7, 127.1, 121.4, 115.3, 110.4, 66.8, 56.2, 56.1, 54.1, 49.1 ppm. HRMS (ESI) *m/z* calculated for C₂₅H₂₉N₂O₅S [(M + H)⁺] 469.1797, found 469.1796.

N-Cyclobutyl-3,4-dimethoxy-N-(4-(morpholinomethyl)benzyl)benze-

nesulfonamide (4a). Yield: 46%. ¹H NMR (CDCl₃): δ 7.43 (dd, J=8, 2Hz, 1H), 7.34–7.25 (m, 5H), 6.94 (d, J=9 Hz, 1H), 4.39 (s, 2H), 4.27 (quintet, J=9 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.75–3.72 (m, 4H), 3.51 (s, 2H), 2.46 (s, 4H), 1.99–1.94 (m, 4H), 1.57–1.52 (m, 2H) ppm. ¹³C NMR (CDCl₃): δ 152.4, 149.0, 137.8, 132.0, 129.4, 127.0, 120.9, 110.6, 109.8, 66.9, 63.0, 56.2, 56.2, 53.5, 52.9, 48.2, 29.2, 15.0 ppm. HRMS (ESI) m/z calculated for C₂₄H₃₃N₂O₅S [(M + H)⁺] 461.2110, found 461.2102.

N-Cyclobutyl-3,4-dimethoxy-N-(3-(morpholinomethyl)benzyl)benze*nesulfonamide* (4 *b*). Yield: 81%. ¹H NMR (CDCl₃): δ 7.43 (dd, J = 8, 2 Hz, 1H), 7.30–7.21 (m, 5H), 6.95–6.93 (d, J = 8 Hz, 1H), 4.39 (s, 2H), 4.28 (quintet, J = 8 Hz, 1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.71 (t, J = 4 Hz, 4H), 3.49 (s, 2H), 2.43 (s, 4H), 1.99–1.92 (m, 4H), 1.55–1.48 (m, 2H) ppm. ¹³C NMR (CDCl₃): δ 152.4, 149.0, 138.7, 137.9, 131.9, 128.4, 128.1, 127.8, 126.0, 120.9, 110.5, 109.7, 67.0, 63.3, 56.2, 56.2, 53.6, 52.9, 48.3, 29.2, 15.0 ppm. HRMS (ESI) *m/z* calculated for C₂₄H₃₃N₂O₅S [(M + H)⁺] 461.2110, found 461.2112.

N-Cyclobutyl-3,4-dimethoxy-N-(2-(morpholinomethyl)benzyl)benze-

nesulfonamide (4c). Yield: 63%. ¹H NMR (CDCl₃): δ 7.56 (d, J = 8 Hz, 1H), 7.47 (dd, J = 8, 2 Hz, 1H), 7.31–7.27 (m, 2H), 7.17 (d, J = 7 Hz, 1H), 6.95 (d, J = 8 Hz, 1H), 4.68 (s, 2H), 4.45 (quintet, J = 8 Hz, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.65 (m, 4H), 3.50 (bs, 2H), 2.42 (bs, 4H), 1.93–1.90 (m, 4H), 1.56–1.50 (m, 2H) ppm. ¹³C NMR (CDCl₃): δ 152.4, 149.0, 138.4, 133.4, 132.1, 130.6, 128.0, 127.4, 126.4, 121.0, 110.5, 109.7, 67.1, 61.6, 56.3, 56.2, 53.5, 52.7, 44.5, 29.0, 15.1 ppm. HRMS (ESI) m/z calculated for $C_{24}H_{33}N_2O_5S$ [(M + H)⁺] 461.2110, found 461.2095.

N-Cyclobutyl-3,4-dimethoxy-N-(4-morpholinobenzyl)benzenesulfo-

namide (4d). Yield: 70%. ¹H NMR (CDCl₃): δ 7.41 (dd, J=8, 2 Hz, 1H), 7.25–7.21 (m, 3H), 6.92 (d, J=9 Hz, 1H), 6.86 (d, J=9, 2H), 4.32 (s, 2H), 4.20 (quintet, J=8 Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.86–3.46 (m, 4H), 3.15–3.12 (m, 4H), 2.02–1.90 (m, 4H), 1.54–1.45 (m, 2H) ppm. ¹³C NMR (CDCl₃): δ 152.4, 150.4, 149.0 132.2, 129.8, 128.2, 120.9, 115.6, 110.6, 109.7, 66.9, 56.2, 56.1, 52.9, 49.4, 48.0, 29.7, 29.3, 15.1 ppm. HRMS (ESI) *m/z* calculated for C₂₃H₃₁O₅N₂S [(M + H)⁺]: 446.1948, found 447.1949.

N-((*2*,*2*-*Dimethyl*-2H-*chromen*-6-*yl*)*methyl*)-*3*,*4*-*dimethoxy*-N-(*2*-*morpholinoethyl*)*benzenesulfonamide* (*5a*). Yield: 49%. ¹H NMR (CDCl₃): δ 7.45 (d, J = 8 Hz, 1H), 6.93 (t, J = 9 Hz, 2H), 6.88–6.85 (m, 1H), 6.67 (d, J = 8 Hz, 1H), 6.22 (d, J = 10 Hz, 1H), 5.59 (d, J = 7 Hz, 1H), 4.23 (s, 2H), 3.93 (s, 3H), 3.89 (s, 3H), 3.59–3.56 (m, 4H), 3.19 (t, J = 7 Hz, 2H), 2.30 (t, J = 7 Hz, 2H), 2.25 (s, 4H), 1.23 (s, 6H) ppm. ¹³C NMR (CDCl₃): δ 152.7, 152.5, 149.1, 131.8, 131.3, 129.1, 128.3, 126.5, 122.0, 121.4, 121.0, 116.3, 110.6, 109.8, 66.8, 57.3, 57.3, 56.3, 56.2, 53.6, 52.2, 44.4, 27.9 ppm. HRMS (ESI) *m/z* calculated for C₂₆H₃₅N₂O₆S [(M + H)⁺] 503.2210, found 503.2204.

N-((*2*,*2*-*Dimethyl*-2H-*chromen*-6-*yl*)*methyl*)-*3*,*4*-*dimethoxy*-N-(*3*-*morpholinopropyl*)*benzenesulfonamide* (*5b*). Yield: 15%. ¹H NMR (CDCl₃): δ 7.43 (d, *J* = 8 Hz, 1H) 6.97 (d, *J* = 8 Hz, 1H), 6.94 (d, *J* = 8 Hz, 1H), 6.87 (s, 1H), 6.68 (d, *J* = 8 Hz, 1H), 6.23 (d, *J* = 10 Hz, 1H), 4.19 (s, 2H), 3.94 (s, 3H), 3.90 (s, 3H), 3.60 (s, 4H), 3.12 (t, *J* = 8, 2H), 2.22 (s, 4H), 2.18 (t, *J* = 7, 2H), 1.59–1.52 (m, 2H), 1.40 (s, 6H) ppm. ¹³C NMR (CDCl₃): δ 152.7, 152.4, 149.1, 131.6, 131.3, 129.3, 128.4, 126.5, 121.9, 121.3, 121.0, 116.3, 110.6, 109.8, 66.9, 56.3, 56.2, 55.9, 53.4, 52.0, 46.2, 28.0, 25.4 ppm. HRMS (ESI) *m/z* calculated for C₂₇H₃₇N₂O₆S [(M + H)⁺] 517. 2367, found 517.2366.

Typical procedure for sulfonylation with 4-morpholinosulfonyl chloride (6a–b)

Amine (1 equivalent) was dissolved in dichloroethane. Pyridine (3 equivalents) and 4-morpholinosulfonyl chloride (1.3 equivalents) were added. The reaction was refluxed for 2 days, then concentrated, taken up in ethyl acetate, washed with saturated NH_4CI and brine, then dried over $MgSO_4$, and concentrated. The residue was then purified by column chromatography in 4:1 hexane/ethyl acetate.

N-((2,2-Dimethyl-2H-chromen-6-yl)methyl)-N-phenylmorpholine-4-

sulfonamide (*6a*). Yield: 17%. ¹H NMR (CDCl₃): δ 7.32–7.25 (m, 5H), 6.90 (d, J = 8 Hz, 1H), 6.83 (s, 1H), 6.65 (d, J = 8 Hz, 1H), 6.25 (d, J = 10 Hz, 1H), 5.60 (d, J = 10 Hz, 1H), 4.70 (s, 2H), 3.63–3.62 (m, 4H), 3.17 (m, 4H), 1.42 (s, 6H) ppm. ¹³C NMR (CDCl₃): δ 131.0, 129.6, 129.2, 129.1, 127.9, 126.9, 122.1, 116.2, 66.3, 56.3, 46.5, 28.0 ppm. HRMS (ESI) *m/z* calculated for C₂₂H₂₇N₂O₄S [(M + H)⁺] 415.1692, found 415.1695.

N-Cyclobutyl-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)morpholine-4-sulfonamide (6b). Yield: 16%. ¹H NMR (CDCl₃): δ 7.04 (dd, J = 8, 2 Hz, 1H), 6.95 (s, 1H), 6.72 (d, J = 8 Hz, 1H), 6.30 (d, J = 10 Hz, 1H), 5.61 (d, J = 10 Hz, 1H), 4.35 (s, 2H), 4.19 (quintet, J = 8 Hz, 1H), 3.63 (t, J = 5 Hz, 4H), 3.09 (t, J = 5 Hz, 4H), 2.13 – 2.06 (m, 4H), 1.60 (m, 2H), 1.41 (s, 6H) ppm. ¹³C NMR (CDCl₃): δ 152.4, 131.2, 130.6, 128.2, 125.5, 122.4, 121.4, 116.4, 76.4, 66.4, 53.0, 48.8, 46.2, 29.6,

Compound	Structure	IC ₅₀ (μM)	cLog D	cLog S
1	OMe N S O2 OMe	~0.6	4.99	-6.37
2	OMe N S O ₂ OMe	~0.3	3.34	-4.53
3a	ON N N S O2 OMe OMe	0.9	3.69	-4.39
3b	O N N S O 2 O Me O Me O Me	>5	3.71	-4.41
3c	OMe ON ON ON ON ON ON ON ON ON ON ON ON ON	>5	3.80	-4.50
3d	O N N N S O ₂ OMe OMe	3.8	3.98	-5.19
4a	ON OME N S O2 OME	1.0	2.94	-3.36
4b	O N N S O 2 O Me O Me O Me	>5	2.96	-3.38
4c	OMe N OMe OMe	>5	3.05	-3.47

Downloaded by [State University NY Binghamton] at 08:03 04 August 2017

(continued)

Compound	Structure	IC ₅₀ (μΜ)	cLog D	cLog S
4d	O N N S O ₂ OMe OMe	2.6	3.24	-4.15
5a		>5	3.13	-4.23
5b		>5	3.17	-4.37
	N S OMe			
ба		>5	2.97	-5.17
6b		>5	2.22	-4.12

28.1, 14.8 ppm. HRMS (ESI) m/z calculated for $C_{20}H_{29}N_2O_4S$ [(M + H)⁺] 393.1843, found 393.1834.

Lipophilicity and solubility prediction

The *in silico* log *D* and log *S* values of all analogs were predicted using Calculator Plugins from MarvinSketch 4.3.0, 2017, ChemAxon (http://www.chemaxon.com), with results detailed in Table 1. Graphical representations of the log *D* and log *S* from pH 0 to 14 are provided in the Supplemental Information.

Luciferase assay

These analogs were first evaluated for their ability to inhibit hypoxia-induced HIF transcriptional activity in LN229-HRE-luciferase glioma cells as described previously^{10–12}. Their inhibitory activities are presented as IC_{50} in Table 1.

Solubility studies using dynamic light scattering

To further investigate the true enhancement of solubility, particle aggregation was examined using dynamic light scattering (DLS).

Selected compounds were treated according to the following procedure:

- All centrifuge tubes and cuvettes were rinsed with either DCM or water and then vacuum dried before use to remove dust and any particulates.
- Stock solutions (10 mM) of each compound of interest were prepared in filtered DMSO.
- 3. Six dilutions (0, 10, 20, 30, 50, and $100 \,\mu$ M) were prepared in filtered de-ionised water with 1% DMSO and allowed to rest at room temperature for 24 h after vortex.
- DLS analysis was performed for each concentration on the Brookhaven Instrument Corporation, NanoBrook 90Plus Particle Size Analyzer, Version 5.20 (Holtsville, NY).
- 5. Additional experiments were performed at specific concentrations for each compound as follows: 0, 1, 3, 10, and $20 \,\mu$ M concentrations of **1**; 0, 10, 12, and $20 \,\mu$ M of **2**; 0, 5, 7, and $10 \,\mu$ M of **3a**; and 0, 10, 20, 30, and $50 \,\mu$ M concentrations of **4a**.
- 6. Additional experiments were repeated in filtered PBS* with 1% DMSO as follows: 0, 0.5, 1, 2, 3, and 5 μ M concentrations of **1**; 0, 5, 7, 10, 12, and 15 μ M of **2**; 0, 10, 12, 15, and 20 μ M of **3a**; and 0, 10, 20, 30, and 50 μ M concentrations of **4a**.



Figure 2. Classes of analogs. (A) Class A, morpholinomethylphenyl in ortho, meta, or para positions, or morpholinophenyl in para position; (B) Class B, morpholinomethylphenyl in ortho, meta, or para positions, or morpholinophenyl in para position; (C) Class C, n = 2 or 3; (D) Class D.

*Experiments in PBS were carried out the same way as the experiments in water except DMSO stock solutions were made at 5 mM and the PBS diluted samples rested for 1 h before particle analysis.

Results and discussion

Design

In considering ways to improve water solubility without compromising potency, we thought about introducing a commonly used morpholino moiety, which is known to help improve water solubility. In doing so, we were interested in searching for the optimal position, which would not negatively affect potency. Therefore, we devised four classes of compounds (Figure 2): Class A incorporates a morpholinomethylphenyl or morpholinophenyl moiety instead of the 2,2-dimethyl-2H-chromene moiety and maintains the N-phenyl group; Class B incorporates either a morpholinomethylphenyl or morpholinophenyl moiety instead of the 2,2-dimethyl-2H-chromene moiety and substitutes the N-phenyl group for an N-cyclobutyl group; Class C has either a 2,2-dimethyl-2H-chromene or N-(2,2-dimethyl-2H-pyrano[3,2-b]pyridin-6-yl) moiety and either an N-ethylmorpholino or N-propylmorpholino group instead of the N-phenyl; and Class D has the 2,2-dimethyl-2H-chromene moiety with a N-phenyl-morpholine-4-sulfonamide.

Chemistry

Synthesis of Class A compounds (Scheme 1) was accomplished in four steps from 2-, 3-, or 4-bromomethylbenzylbromide **7a-c** or in two steps from 4-morpholinobenzaldehyde **9d**. Intermediates **7a-c** were substituted with morpholine to yield morpholinomethylbenzylbromides **8a-c** in quantitative yield. Next, the phenyl bromides **8a-c** were converted to benzaldehydes **9a-c** via lithium-halogen exchange at -78 °C under inert gas. The aryllithium intermediate was treated with DMF as the electrophile *in situ* to generate the final benzaldehydes **9a-c**. The aldehydes **9a-d** underwent reductive amination with aniline to afford the secondary amines **10a-d**. Finally, **10a-d** were reacted with 3,4-dimethoxybenzenesulfonyl chloride to afford sulfonamides **2a-d**. Class B compounds (Scheme 1(C)) were synthesised in almost the same fashion as Class A, except that reductive amination of **9a-d** was with cyclobutylamine and was not catalysed by any Lewis acid.

Class C compounds were synthesised (Scheme 2) from 2,2-dimethyl-2*H*-chromene-6-carbaldehyde **12**, which was readily synthesised from published procedures¹³. The aldehyde **12** underwent reductive amination with either ethylaminomorpholine or propylaminomorpholine to give secondary amines **13a–b**, which were then reacted with 3,4-dimethoxybenzenesulfonyl chloride to afford sulfonamides **5a–b**.

Class D compounds were synthesised (Scheme 3) from 12 in two steps. First, 12 underwent reductive amination with either aniline or cyclobutylamine to give secondary amines 14a-b. Next, the amines 14a-b were reacted with 4-morpholinosulfonyl chloride to afford sulfonamides 6a-b.

Biology

All the analogs were assessed for their ability to inhibit the HIF-1 pathway using a luciferase reporter assay described previously¹⁰. This assay reports the ability for a compound to inhibit HIF transcriptional activity. However, it does not specifically reveal the mode of action at the biochemical level. As can be seen from Table 1, introduction of a morpholino unit on the sulfonamide nitrogen led to compounds (5) with substantially diminished activity. The same is true if the morpholino unit is directly attached to the sulfonyl group (6). In the two series of compounds (3, 4) with a substituted phenyl group replacing the benzopyran ring in 1, only introduction of the morpholino moiety at the para positions (3) allowed for the preservation of HIF inhibition activity. Indeed, compounds 3a and 3d, which have exchanged the benzopyran ring for a para-morpholinomethylphenyl and para-morpholinophenyl, respectively, exhibit IC_{50} values of 0.9 and 3.8 μ M. Similarly, analogs 4a and 4d, which replace the N-phenyl with a N-cyclobutyl, but are otherwise structurally the same as 3a and 3d, have IC_{50} values of 1.0 and ${\sim}2.6\,\mu\text{M},$ respectively. No other



Scheme 1. Synthesis of Class A & B compounds. (A) Synthesis of precursors. (B) Synthesis of Class A. (C) Synthesis of Class B. Reagents and conditions: (a) morpholine, K_2CO_3 , ACN, room temperature, overnight; (b) BuLi, DMF, THF, $-78 \degree C$, 1 h; (c) aniline, $InCl_3$, $NaBH_4$, ACN, 20 min; (d) 3,4-dimethoxybenzenesulfonyl chloride, K_2CO_3 , DCM, overnight; (e) cyclobutylamine, $NaBH_4$, MeOH, overnight.



Scheme 2. Synthesis of Class C compounds. Reagents and conditions: (a) amine, NaBH₄, MeOH, overnight; (b) 3,4-dimethoxybenzenesulfonyl chloride, K₂CO₃, DCM, overnight.



Scheme 3. Synthesis of Class D compounds. Reagents and conditions: (a) aniline, InCl₃, NaBH₄, ACN, 20 min or cyclobutylamine, NaBH₄, MeOH, overnight; (b) 4-morpholinosulfonyl chloride, pyridine, DCE, reflux 2 days.





Figure 3. Structures of compounds used for dynamic light scattering.

T-LL-D	MAR A STATE A	and the letter of			
Table 2.	measured	Solubility	OI.	selected	compounds

Name	Concentration of particle appearance in water (µM)	Concentration of particle appearance in PBS (µM)
1	1	1
2	10	10
3a	10	15
4a	>100	>50

analogs synthesised in this work exhibited HIF inhibitory activity with IC₅₀ lower than 5 μ M, suggesting the importance of conserving electronic and/or steric effects para to the phenyl ring. In particular, compounds **3a** and **4a** are active within the same order of magnitude as **1**, and are about threefold less active than the previously discovered **2** (IC₅₀ = ~0.3 μ M)¹². The improved potency of **3a** and **4a** over **3d** and **4d** suggests a possible role for flexibility of the ligand in the binding site.

To gain some initial understanding of lipophilicity and solubility, the predicted log *D* and log *S* values were calculated for **1**, **2**, and their analogs. Log *P* refers to a molecule's partition coefficient, or the log of the ratio between its solubility in octanol versus water¹⁴. This is commonly used to indicate a candidate drug's lipophilicity, and a log *P* or cLog *P* (calculated log *P*) less than 5 is generally considered "drug-like"¹⁵. For ionizable small molecules, log *D* is the distribution constant, which describes the partition coefficient at different pH levels¹⁶. A molecule's water solubility is typically measured at room temperature (20–25 °C) in mol/L and represented as log *S*, or clog *S* when calculated computationally. Drugs on the market with a variety of structures typically possess a log *S* between -5 and -2^{17} .

Though several of the morpholine analogs have very drug-like properties, most are not active in the luciferase assay. Only **3a**, **3d**, **4a**, and **4d** are active toward the HIF pathway and only **3a** and **4a** show comparable IC_{50} values as **1**. Therefore, we examined their solubility in water and phosphate buffered saline (PBS).

Solubility studies

To investigate the true enhancement of aqueous solubility, particle aggregation was examined using DLS. DLS can detect particle sizes in solution by measuring changes in scattered light in relation to the Brownian motion of particles¹⁸. It is commonly used to detect the particle sizes of various chemical and biological molecules, including small molecule inhibitors¹⁹. Though there are



 \tilde{O}_2

 $\overset{\circ}{O}_2$

64b, 2

4a

OMe

OMe

OMe

OMe

The active compounds 3a and 4a were compared to their nonmorpholine containing counterparts, 1 and 2, respectively (Figure 3). Solutions of varying concentrations of each compound were made in either water or PBS with 1% DMSO. Each solution was measured in the particle size analyser to identify which samples showed formation of aggregates in solution. DLS measurements, summarised in Table 2, reveal that 3a forms aggregates at approximately $10 \mu M$, an order of magnitude higher than **1**, which is insoluble at just 1 µM in water. The N-cyclobutyl analog 4a forms aggregates in excess of $100 \,\mu$ M, significantly higher than its counterpart 2, which forms particles at a mere 10 µM. In PBS, the solubilities parallel those seen in the water solution, where 1 and **3a** exhibit comparable particle formation at $1 \mu M$ and $15 \mu M$, respectively. 2 shows particle formation at 10 µM, while 4a shows none at this concentration, as expected. Indeed, with a $\log D$ of 2.94 log S of -3.36 (Table 1), 4a is predicted to be quite soluble in aqueous solutions.

The described results clearly indicate that (1) the benzopyran ring can be modified with minimal loss of activity and (2) the para position of the phenyl ring can tolerate substantial changes and can be used for improvement of water solubility. Such results will help future optimisation work.

Conclusion

Of the 12 new morpholine-containing analogs developed in this work, four demonstrate HIF inhibition in the low or sub-micromolar range. In particular, 3a and 4a both exhibit inhibition of HIF transcriptional activity with IC₅₀ values of 0.9 and $1.0\,\mu\text{M}$, respectively. As expected, the in silico log P and log S values of these analogs are considered more favourable than lead compound 1 or its more potent analog 2, and are therefore likely to be more bioavailable. Following these indications, solubility as measured by particle detection with DLS reveal the exceptional solubility of analogs 3a and 4a over their non-morpholine containing predecessors 1 and 2. Particle formation of 4a is undetected in excess of $100 \,\mu$ M in water and $50 \,\mu$ M in PBS, while still displaying HIF inhibition in the same order of magnitude as lead 1. These results encourage exploration and use of more soluble moieties to further probe the SAR (structure-activity relationship) and SSR (structure-solubility relationship) of potential analogs.

Acknowledgements

Financial support from the National Institutes of Health (1R01CA180805-01, 5R01CA176001-04), the CURE Childhood Cancer, Alan B. Slifka, Samuel Waxman Cancer Research, and V Foundations (to EGVM) and the Antinori Winship Invest pilot grant (to SK) are gratefully acknowledged. The laboratories of Didier Merlin and Hamed Laroui are especially acknowledged for the use of and guidance with their dynamic light scattering instruments. JHF and SKZ also acknowledge internal fellowships: Department of Education GAANN grant (P200A120122) with Barbara Baumstark as PI in support of JHF and GSU MBD and CDT programs to SKZ.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

Financial support from the National Institutes of Health (1R01CA180805-01, 5R01CA176001-04), the CURE Childhood Cancer, Alan B. Slifka, Samuel Waxman Cancer Research, and V Foundations (to EGVM) and the Antinori Winship Invest pilot grant (to SK) are gratefully acknowledged. The laboratories of Didier Merlin and Hamed Laroui are especially acknowledged for the use of and guidance with their dynamic light scattering instruments. JHF and SKZ also acknowledge internal fellowships: Department of Education GAANN grant (P200A120122) with Barbara Baumstark as PI in support of JHF and GSU MBD and CDT programs to SKZ.

ORCID

Jalisa H. Ferguson () http://orcid.org/0000-0002-4095-4357 Erwin G. Van Meir () http://orcid.org/0000-0003-2444-7707 Sarah K. Zingales () http://orcid.org/0000-0002-4908-6226 Binghe Wang () http://orcid.org/0000-0002-2200-5270

References

- 1. Siegel R, Jemal A. Cancer Facts & Figures 2012. American Cancer Society: Atlanta; 2012.
- 2. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009;107:1053–62.
- (a) Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225–39. (b) Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601–5. (c) Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
- Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230–7.
- Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510–14.
- Maxwell PH, Wiesener MS, Chang G-W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271–5.
- 7. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.

- Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–32.
- Nicolaou KC, Pfefferkorn JA, Mitchell HJ, et al. Natural product-like combinatorial libraries based on privileged structures.
 Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 2000;122:9954–67.
- (a) Tan C, de Noronha RG, Devi NS, et al. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett 2011;21:5528–32. (b) Narita T, Yin S, Gelin CF, et al. Identification of a novel small molecule HIF-1α translation inhibitor. Clin Cancer Res 2009;15:6128–36.
- 11. (a) Wang W, Ao L, Rayburn ER, et al. KCN1, a novel synthetic sulfonamide anticancer agent: *in vitro* and *in vivo* anti-pancreatic cancer activities and preclinical pharmacology. PLoS One 2012;7:e44883. (b) Zhang Q, Kaluz S, Yang H, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 α interaction with cofactors p300/CBP. Clin Cancer Res 2012;18: 6623–33.(c) Yin S, Kaluz S, Devi NS, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 α interaction with co-factors p300/CBP. Clin Cancer Res 2012;18: 6623–33.(c) Yin S, Kaluz S, Devi NS, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 α interaction with co-factors p300/CBP. Clin Cancer Res 2012;18:6623–33.
- Mooring SR, Jin H, Devi NS, et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem 2011;54:8471–89.
- (a) Ferguson J, De Los Santos Z, Devi N, et al. Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway. Bioorg Med Chem Lett 2017;27:1731–6. (b) Prado S, Janin YL, Saint-Joanis B, et al. Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. Bioorg Med Chem 2007;15:2177–86.
- 14. (a) Sangster J. Octanal-water partition coefficients of small organic compounds. J Phys Chem Ref 1989;18:1111–227. (b) Acree WE, Grubbs LM, Abraham MH. Prediction of partition coefficients and permeability of drug metabolites in biological systems with Abraham model solute descriptors derived from measured solubilities and water-to-organic solvent partition coefficients. In: Acree B, ed. Toxicity and drug testing. InTech. Available from: http://www.intechopen.com/books/toxicity-and-drug-testing/prediction-of-partition-coefficients-and-permeability-of-drug-molecules-in-biological-systems-with-a
- Lipinksi CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25.
- 16. Bhal SK, Kassam K, Peirson IG, Pearl GM. The rule of five revisited: applying log *D* in place of log *P* in drug-likeness filters. Mol Pharm 2007;4:556–60.
- Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997;86:450.
- Pecora R. Dynamic light scattering measurement of nanoparticles in liquids. J Nano Res 2000;2:123–31.
- Berne BJ, Pecora R. Dynamic light scattering: with applications to chemistry, biology, and physics. North Chelmsford: Courier Corporation; 2000.